Current Partnering Knowledge Center
The Leading Partnering Intelligence Platform for Life Science Dealmakers
The leading partnering intelligence platform for life science dealmakers
The Current Partnering Knowledge Center is the industry-standard platform for benchmarking and analyzing life science transactions trusted by pharma, biotech, and advisory teams worldwide to support high-value dealmaking decisions.
Bringing together the full power of the Current Partnering report library the platform provides structured, searchable access to real-world licensing, collaboration, alliance, and M&A transactions - enabling teams to move faster, negotiate smarter, and operate with confidence.
Move beyond headline deal values
Most sources provide high-level summaries.
The Knowledge Center delivers full transparency into how deals are actually structured, allowing you to understand not just what was paid, but how and why agreements are constructed.
This includes:
-
Upfront payments, milestones, and royalty structures
-
Rights granted and retained
-
Development and commercialization responsibilities
-
Option structures and evaluation frameworks
-
Manufacturing, supply, and co-development provisions
-
Direct access to SEC-filed agreements and source documents
This level of detail enables you to accurately benchmark comparable transactions and understand how value, risk, and control are allocated in real-world deals.
Built for real-world BD, licensing, and strategy teams
The Knowledge Center is designed to support decision-making across the full deal lifecycle. Teams use the platform to:
-
Benchmark transactions and validate deal assumptions
-
Prepare for negotiations using real market precedents
-
Identify and prioritize licensing or acquisition targets
-
Assess counterparties and competitive deal activity
-
Support valuation with defensible, evidence-based data
-
Inform internal strategy and investment decisions
Whether evaluating a single opportunity or shaping broader partnering strategy, the platform provides immediate access to the data needed to act with confidence.
Comprehensive coverage across the partnering landscape
Subscribers gain access to a continuously updated intelligence platform covering:
-
Licensing and collaboration agreements
-
Co-development and co-promotion deals
-
M&A and asset acquisitions
-
Joint ventures and strategic alliances
-
Manufacturing and supply agreements
-
Option and evaluation deals
-
Royalty benchmarks and financial structures
Coverage spans the full life sciences landscape, including oncology, CNS, immunology, metabolic disease, cell and gene therapy, diagnostics, drug delivery, and precision medicine... see the full list in the table below.
Continuously updated, analyst-driven intelligence
The Knowledge Center is maintained by Current Partnering’s in-house analyst team, ensuring ongoing coverage of new transactions, updated benchmarks, and newly available contract disclosures.
Subscribers also receive access to the full portfolio of 66 Current Partnering reports, updated on a rolling basis to support continuous benchmarking and market monitoring.
Trusted by life science companies worldwide
Current Partnering has been supporting the life sciences industry since 2007 providing deal intelligence to global pharmaceutical companies, emerging biotechs, investors, and advisory firms.
The Knowledge Center is widely used by BD and licensing teams, strategy groups, and executive leadership to support critical dealmaking decisions.
Gain a stronger position in every negotiation
By combining comprehensive deal coverage, contract-level insight, and continuously updated intelligence, the Current Partnering Knowledge Center provides the evidence base required to benchmark effectively, structure competitive deals, and negotiate from a position of strength.
As part of your Knowledge Center access, you will have access to our complete dealmaking report library below, all of which are updated on a rolling six-month schedule for ongoing deal term monitoring:
To inquire about how this will benefit your organization, get in touch and we will respond as soon as possible.
By subscribing to the CP Knowledge Center intelligence platform, users can:
- Track and monitor partnering activity by company A-Z, technology, therapy, deal type and stage of development at signing
- Understand agreed deal terms including headline, upfront, milestone and royalties where available
- Make huge savings on your partnering intelligence spend
- Save countless hours on conducting due diligence and benchmarking analysis
- Instantly access our complete library of partnering reports through our online portal
- Receive new and updated report titles for the 12 month subscription period
- Create your own presentations by utilizing information from our reports
- Access full contract documents as provided to the SEC by the deal parties
- Become a dealmaking expert across multiple therapeutic and technology areas
As a CP Knowledge Center intelligence platform subscriber users have access to:
-
- CP Reports: 66 in-depth partnering terms reports including deal data collated, presented and analysed
- Deal type reports (licensing, M&A, collaborative R&D, royalty rates, asset purchase etc)
- Technology-based dealmaking reports (biomarkers, vaccines, companion diagnostics etc)
- Therapy-based dealmaking reports (oncology, CNS, dermatology, psychiatry etc)
- Stage of development reports (discovery, preclinical, clinical)
- Industry sector reports (academic and non-profit, animal health, big pharma, specialty pharma)
- CP Reports: 66 in-depth partnering terms reports including deal data collated, presented and analysed
Updated versions of report titles are automatically added to Knowledge Center download area - updated every six months
Contact us for details.
A full explanation of license type definitions can be found here.
Upgrade an existing subscription? Contact us now to discuss options.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
All card payments are processed using Stripe.
Sales Support
If you have any questions we will do our best to resolve your query. Contact us direct.
About Current Partnering
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
- Company press releases and announcements
- SEC filings and equivalent regulatory disclosures
- Company and investor presentations
- Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
- Licensing and co-development
- Research and collaborative R&D
- Manufacturing, supply, and distribution
- Commercialisation and co-promotion
- Equity investments, joint ventures, and asset transactions
- Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
- Financial terms — including upfront payments, milestones, and royalties
- Rights allocation — development, manufacturing, and commercialization responsibilities
- Deal structure — exclusivity, territorial scope, and agreement type
- Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
- Therapy area and technology type
- Stage of development
- Asset type and deal components
- Geographic scope and exclusivity
- Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
- How financial mechanisms are defined and triggered
- How responsibilities are operationalised between parties
- How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:
- Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
- Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
- Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight
Common use cases include:
- Benchmarking comparable transactions
- Supporting valuation and deal structuring
- Preparing for negotiations
- Evaluating potential partners
- Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.
